PVR and cancer: Considering the predominant role of the TIGIT/CD155/DNAM-1 axis in the immunosuppression in tumors, including OC, the inhibition of the pathway in monotherapy or combined therapy, especially altogether with the programmed cell death pathway blockade, the ICP inhibitors are a potential target in cancer treatment, in particular in cold tumors [20].